脊柱关节炎中英夫利西单抗的治疗药物监测:文献综述
本文综述英夫利西单抗(IFX)血清浓度与脊柱关节炎疾病活动度的关系。IFX药代动力学变异大,临床应答随谷浓度升高而增加,但脊柱关节炎领域的目标浓度尚未明确。
要点
- IFX药代动力学高度可变,影响慢性炎症疾病的临床应答。
- 在RA、AS、IBD和银屑病患者中,临床应答随IFX谷浓度升高而增加。
- RA、CD和UC已提出预测良好临床应答的目标浓度,脊柱关节炎尚待明确。
核心结论
- IFX药代动力学高度可变并影响慢性炎症疾病的临床应答,但脊柱关节炎中预测良好应答的目标浓度尚未提出。
研究设计与样本
- 本文为文献综述,检索并汇总关于IFX血清浓度及其相关参数与脊柱关节炎患者疾病活动度关系的现有文献。
主要发现
- 在RA、强直性脊柱炎、炎症性肠病和银屑病患者中,临床应答随IFX谷浓度升高而增加。
- RA、克罗恩病和溃疡性结肠炎中已提出预测良好临床应答的目标浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Available evidence indicates that a therapeutic drug monitoring strategy leads to major cost savings related to the anti-tumour necrosis factor-α therapy in both inflammatory bowel disease and rheumatoid arthritis (RA) patients, with no negative impact on efficacy. However, although the systematic use of therapeutic drug monitoring could potentially be beneficial and economically acceptable to drug dose optimization, it is not justifiable for all drugs. Infliximab (IFX) is a chimeric monoclonal immunoglobulin G1 targeting tumour necrosis factor. It has been approved for the treatment of immuno-inflammatory diseases, including RA, ankylosing spondylitis, psoriatic arthritis, Crohn's disease and ulcerative colitis. IFX's pharmacokinetics is highly variable and influences clinical response in chronic inflammatory diseases. Clinical response increases with IFX trough concentrations in RA, ankylosing spondylitis, inflammatory bowel disease and psoriatic patients. Target concentrations predictive of good clinical response were proposed in RA, Crohn's disease and ulcerative colitis. The purpose of this article is to review the current literature surrounding IFX serum concentrations and their related parameters with disease activity in patients with spondyloarthritis. Gathering information about the efficacy of IFX in patients with spondyloarthritis and relating IFX serum concentrations to disease activity were the main goals of this study.
引用
- Fobelo Lozano MJ, Serrano Giménez R, Sánchez Fidalgo S, et al. Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature. Br J Clin Pharmacol. 2019. PMID: 31315147. doi:10.1111/bcp.14062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。